McKesson, the largest U.S. pharmaceutical distributor, is facing some major headwinds these days. After years of strong sales growth thanks to generic drug price inflation, that tailwind is expected to slow and cut into the company’s overall revenue growth this year. McKesson also recently lost a handful of customers and could potentially lose another $13 billion worth of revenue in 2018 when (or if) Rite Aid is acquired by Walgreens. Management has been working on a series of maneuvers to lessen these blows, including acquiring strategic bolt-on companies to replace lost business and implementing a restructuring plan that’s expected to generate about $180 million in savings this fiscal year.
CEO
John H. Hammergren
Sector
Wholesalers
Industry
Wholesalers: Health Care
HQ Location
San Francisco, CA
Employees
68,000
Website
Years on Global 500 List
22
